TriangleIvonescimab (NCT07655570)
Ivonescimab trial for Cutaneous Angiosarcoma (NCT07655570). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with advanced, metastatic, or unresectable cutaneous angiosarcoma after paclitaxel or docetaxel. Previous PD-1 or PD-L1 treatment is excluded.
The idea: ivonescimab targets PD-1, an immune brake, and VEGF, a signal involved in tumor blood-vessel growth. Patients receive an intravenous infusion every three weeks. Researchers measure tumor responses and side effects. Participation in a companion tissue-study protocol is required. Treatment continues until progression, unacceptable toxicity, or another stopping condition.
This phase 2 study plans 10 patients. Michael Nakazawa leads at MD Anderson in Houston, the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.